RCUS (35) PBH (72) HCM (46) PGEN (35) ⌘ Pro Terminal →

Pharvaris N.V. (PHVS) — RQD Stock Rating Cockpit

$33.58 +2.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pharvaris N.V. (PHVS) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $2.34B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHVS)Realized 20D OHLCV Swing Band: ±9.1%

RSI-14 MOMENTUMBULLISH MOMENTUM

59.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE57% OF RANGE

L: $21$33.58H: $43

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PHVS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (63)

23/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PHVS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PHVS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PHVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.29%📐 HORIZONTAL RANGE

2026-10-30O $33.48H $33.94L $33.05C $33.58VOL 1.48M

RES: $47.96SUP: $26.96SMA50: $33.66SMA200: $31.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHVS Butterfly Map → + Track PHVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PHVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PHVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHVS)

Health Care Rank #157 of 1016 ⚔️ RCUS vs PHVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHVS vs. RCUS, PBH, HCM, PGEN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pharvaris N.V. (PHVS) ranks #157 by composite RQD confidence (63/100, grade C) and #232 by equity capitalization ($2.34B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with PHVS at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PHVS ACTIVE Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	Benchmark Subject
RCUS Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-phvs →
PBH Prestige Consumer Healthcare Inc.	B	72/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	/pbh-vs-phvs →
HCM HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-phvs →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-phvs →

2. PHVS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Pharvaris N.V. (PHVS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.34B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PHVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pharvaris N.V. (NASDAQ: PHVS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $33.58 (+2.32% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHVS ranks #157 in composite RQD confidence.

How does PHVS compare to RCUS and PBH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHVS carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RCUS (Arcus Biosciences Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B) and PBH (Prestige Consumer Healthcare Inc.) posts a B grade (72/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.31B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PHVS?

For Pharvaris N.V. (PHVS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #157 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PHVS trading relative to its 50-day, 200-day, and 52-week technical levels?

PHVS last traded at $33.58 (+2.32% on volume of 879,103 shares), positioning the stock -0.24% below its 50-day simple moving average ($33.66) and +8.32% above its 200-day simple moving average ($31.00). Across its 52-week range of $21.02 to $43.25, PHVS sits at the 56.5% percentile with a 14-day RSI of 59.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.1% ($30.52 to $36.64).

PHVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PHVS stock right now?

Pharvaris N.V. (PHVS) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is PHVS's 12-month price target and RQD AI Jury consensus?

PHVS's 12-month base price target is $34.34 (range $26.79 to $45.41), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PHVS RQD Cockpit PHVS 12M Forecast PHVS Earnings & Move PHVS Dividends & DRIP PHVS Insiders & 13F PHVS Whale Options PHVS Profit Sankey PHVS News & Why